A previous transcriptomic study in RRMS patients found a similar number of DEGs (478) at 6 weeks of DMF treatment, which were enriched for transcripts related to the nuclear factor E2-related factor 2 (Nrf2) and NF-kB pathways (34). Here, NFKB1 is linked to relapsing-remitting multiple sclerosis.